|Table of Contents|

The prognostic value of PD-L1 expression for patients with esophageal cancer：A Meta-analysis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2017 01
Page:
48-51
Research Field:
Publishing date:

Info

Title:
The prognostic value of PD-L1 expression for patients with esophageal cancer：A Meta-analysis
Author(s):
Wei Yu; Zhang Li
VIP Department of Internal Medicine，First Affiliated Hospital，Xinjiang Medical University，Xinjiang Urumqi 830054，China.
Keywords:
programmed cell denth-ligand; esophageal cancer; prognosis; Meta-analysis
PACS:
R735.1
DOI:
10.3969/j.issn.1672-4992.2017.01.013
Abstract:
Objective：To study the value of programmed cell death-ligand 1(PD-L1）expression to evaluate the prognosis of the patients with esophageal cancer.Methods：The papers related to PD-L1 expression and the prognosis of esophageal cancer were searched through PubMed，the Cochrane Library，Web of science，Wanfang data and CNKI to collect retrospective cohort studies.The bias of data was analyzed by using RevMan5.3 software，Begg's funnel plot and Egger's methods.Results：Total 6 cohort studies including 1 119 patients were analyzed.The results showed that the PD-L1 protein's high expression was leading to a poor overall survival rate（HR=1.90，95%CI：1.28~2.81，P=0.001).But it was not related to gender，degree of tumor invasion，lymph node metastasis，TNM staging.However，a high expression of PD-L1 was significantly correlated to the distant metastasis(M0 vs M+).Conclusion：A high level of PD-L1 protein expression might be a risk prognostic factor for patients with esophageal cancer.It also implied that PD-L1 potentially might be a prognostic marker and a new therapeutic target.

References:

［1］Wu M，Liu AM，Kampman E，et al.Green tea drinking，high tea temperature and esophageal cancer in high and low risk areas of Jiangsu province，China：A popula-tion based case control study［J］.Int J Cancer，2009，124(8)：1907-1913.
［2］Song Y，Li L，Ou Y，et al.Identification of genomic alterations in oesophageal squamous cell cancer［J］.Nature，2014，509(7398)：91-95.
［3］Xu Y，Yu X，Chen Q，et al.Neoadjuvant versus adjuvant treatment：Which one is better for resectable esophageal squamous cell carcinoma［J］?World J Surg Oncol，2012，10(1)：173.
［4］Ohigashi Y，Sho M，Yamada Y，et al.Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer［J］.Clin Cancer Res，2005，11(8)：2947-2953.
［5］Ascierto PA，Asseo R，Carteni G，et al.The role of immunotherapy in solid tumours：Report from the Campania Society of Oncology Immunotheraoy(SCITO）meeting，Naples 2014［J］.J Transl Med，2014，12(1)：291.
［6］Chen L，Deng H，Lu M，et al.B7-H1 expression associates with tumor invasion and predicts patient's survival in human esophageal cancer［J］.Int J Clin Exp Pathol，2014，7(9)：6015-6023.
［7］Chen K，Cheng G，Zhang F，et al.Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma［J］.Oncotarget，2016，7(21)：3070-3072.
［8］Parmar MK，Torri V，Stewart L，et al.Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints［J］.Stat Med，1998，17(24)：2815-2834.
［9］Altman DG，Bland JM.Interaction revisited：The difference between two estimates［J］.BMJ，2003，326(7382)：219.
［10］Loos M，Langer R，Schuster T，et al.Clinical significance of the costimulatory molecule B7-H1 in Barrett carcinoma［J］.Ann Thorac Surg，2011，91(4)：1025-1031.
［11］Chen MF，Chen PT，Chen WC，et al.The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression［J］.Oncotarget，2016，7(7)：7913-7924.
［12］Tanaka K，Miyata H，Sugimura K，et al.Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy［J］.Cancer Sci，2016，107(6)：726-733.
［13］Cho Y，Miyamoto M，Kato K，et al.CD4+ and CD8+ T cells cooperate to improve prognosis of patientswith esophageal squamous cell carcinoma［J］.Cancer Res，2003，63(7)：1555-1559.
［14］Schumacher K，Haensch W，Roefzaad C，et al.Prognostic significance of activated CD8(+）T cell infiltrations within esophageal carcinomas［J］.Cancer Res，2001，61(10)：3932-3936.
［15］Ropponen KM，Eskelinen MJ，Lipponen PK，et al.Prognostic value of tumour-infiltrating lymphocytes(TILs）in colorectal cancer［J］.J Pathol，1997，182(3)：318-324.
［16］Carter L，Fouser LA，Jussif J，et al.PD-1：PD-L inhibitory pathway affects both CD4(+）and CD8(+）T cells and is overcome by IL-2［J］.Eur J Immunol，2002，32(3)：634-643.
［17］Latehman Y，Wood CR，Chernova T，et al.PD-L2 is a second ligand for PD-1 and inhibits T-cell activation［J］.Nat Immunol，2001，2(3)：261-268.
［18］Dong H，Zhu G，Tamada K，et al.B7-H1，a third member of the B7 family，costimulates T-cell proliferation and interleukin-10 secretion［J］.Nat Med，1999，5(12)：1365-1369.
［19］Aranda F，Vacchelli E，Eggermont A，et al.Trial Watch：Immunostimulatory monoclonal antibodies in cancer therapy［J］.Oncoimmunology，2014，3(1)：e27297.
［20］Gettinger S，Herbst RS.B7-H1/PD-1 blockade therapy in non-small cell lung cancer：current status and future direction［J］.Cancer J，2014，20(1)：281-289.
［21］Topalian SL，Hodi FS，Brahmer JR，et al.Safety，activity，and immune correlates of anti-PD-1 antibody in cancer［J］.N Engl J Med，2012，366(2)：2443-2454.

Memo

Memo:
国家自然科学基金资助项目(编号：81460754)
Last Update: 2016-12-01